- Home
- IMUX vs VERI Comparison
IMUX vs VERI Comparison
Compare IMUX & VERI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- VERI
- Stock Information
- Founded
- IMUX 2016
- VERI 2014
- Country
- IMUX United States
- VERI United States
- Employees
- IMUX N/A
- VERI N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- VERI EDP Services
- Sector
- IMUX Health Care
- VERI Technology
- Exchange
- IMUX Nasdaq
- VERI Nasdaq
- Market Cap
- IMUX 135.1M
- VERI 158.0M
- IPO Year
- IMUX N/A
- VERI 2017
- Fundamental
- Price
- IMUX $1.59
- VERI $4.17
- Analyst Decision
- IMUX Strong Buy
- VERI Hold
- Analyst Count
- IMUX 6
- VERI 1
- Target Price
- IMUX $12.17
- VERI $2.25
- AVG Volume (30 Days)
- IMUX 460.8K
- VERI 826.7K
- Earning Date
- IMUX 11-12-2024
- VERI 11-06-2024
- Dividend Yield
- IMUX N/A
- VERI N/A
- EPS Growth
- IMUX N/A
- VERI N/A
- EPS
- IMUX N/A
- VERI N/A
- Revenue
- IMUX N/A
- VERI $131,958,000.00
- Revenue This Year
- IMUX N/A
- VERI $10.27
- Revenue Next Year
- IMUX N/A
- VERI $2.47
- P/E Ratio
- IMUX N/A
- VERI N/A
- Revenue Growth
- IMUX N/A
- VERI N/A
- 52 Week Low
- IMUX $0.95
- VERI $1.48
- 52 Week High
- IMUX $2.11
- VERI $7.76
- Technical
- Relative Strength Index (RSI)
- IMUX 54.40
- VERI 55.61
- Support Level
- IMUX $1.35
- VERI $3.66
- Resistance Level
- IMUX $1.53
- VERI $5.64
- Average True Range (ATR)
- IMUX 0.11
- VERI 0.48
- MACD
- IMUX -0.01
- VERI 0.01
- Stochastic Oscillator
- IMUX 64.86
- VERI 35.32
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About VERI Veritone Inc.
Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has a presence in the United States, the United Kingdom, France, Australia, Israel and India.